Previously, we showed that combinatorial treatment with the CDK4/6 inhibitor palbociclib (PB) and differentiation-inducing agent retinoic acid (RA) inhibits proliferation and drives neuronal differentiation of ADRN neuroblastoma cell lines, to a greater extent than either agent alone7. This evidence concerns the gene CDK4 and neuroblastoma.